Phase 2 study of guadecitabine (SGI-110), a novel hypomethylating agent, in treatment-naïve patients with acute myeloid leukaemia who are not candidates for intensive chemotherapy

BACKGROUND: Hypomethylating agents azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia (AML), but responses are limited and of short duration, possibly due to short half-lives and suboptimal bone marrow exposure. Guadecitabine (SGI-110), a dinucleo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Oncol
Päätekijät: Kantarjian, Hagop M, Roboz, Gail J, Kropf, Patricia L, Yee, Karen WL, O’Connell, Casey L, Tibes, Raoul, Walsh, Katherine J, Podoltsev, Nikolai A, Griffiths, Elizabeth A, Jabbour, Elias, Garcia-Manero, Guillermo, Rizzieri, David, Stock, Wendy, Savona, Michael R, Rosenblat, Todd L, Berdeja, Jesus G, Ravandi, Farhad, Rock, Edwin P, Hao, Yong, Azab, Mohammad, Issa, Jean-Pierre J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5925750/
https://ncbi.nlm.nih.gov/pubmed/28844816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30576-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia